Ivosidenib Overview |Biomedgrid

Isocitrate dehydrogenase 1 (IDH1) is an enzyme that stimulates the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG). The mutation in IDH1 provokes uncontrollable cell proliferation and is recorded in ∼6% to 10% of patients with AML [1]. Ivosidenib (AG-120) is an oral, reversible small-molecule inhibitor of mutated IDH1 enzyme. In July of 2018, ivosidenib received the FDA approval for the treatment of refractory or relapsed AML (R/R AML) patients with IDH1 mutation [2]. The approval was established on results of a multicenter clinical trial with 179 patients. The Complete Response (CR) rate made up 24.7% while the Complete Response with partial hematologic improvement (СRh) rate was 8%.